# Zai Lab Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Zai Lab Ltd). ## Overview Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for oncology, immunology, neuroscience, and infectious diseases. The company operates through a network of subsidiaries and commercial infrastructure centered in Greater China, with manufacturing and development activities in Suzhou, China. ## Products & services • ZEJULA (niraparib) • VYVGART / VYVGART Hytrulo • NUZYRA • OPTUNE • QINLOCK • XACDURO • AUGTYRO - **Oncology products** (65%) — Cancer therapies including ZEJULA, QINLOCK, OPTUNE, and AUGTYRO. - **Immunology products** (20%) — Autoimmune and neuromuscular therapies including VYVGART and VYVGART Hytrulo. - **Infectious disease products** (12%) — Anti-infective therapy including NUZYRA and XACDURO. - **Other commercial and patient-program products** (3%) — Pre-commercial or other product sales and collaboration-related revenue. - ZEJULA (niraparib) PARP inhibitor for oncology - VYVGART / VYVGART Hytrulo for autoimmune disease - NUZYRA antibiotic for serious bacterial infections - OPTUNE tumor treating fields therapy - QINLOCK, XACDURO, and AUGTYRO oncology/infectious products ## Customers Zai Lab sells primarily to third-party distributors, who then supply healthcare providers and hospitals, mainly in mainland China. Its commercial products are used in hospital and specialty-care settings, where access, reimbursement, and distributor coverage are important to adoption. - **Pharmaceutical distributors** (primary) — Buy finished products for resale into hospital and retail channels; they are the direct customers and manage inventory and distribution. - **Hospitals and medical centers** (primary) — End users of the therapies, especially major medical centers across Greater China that drive uptake of specialty medicines. - **Healthcare providers and specialists** (primary) — Oncologists, neurologists, immunologists, and infectious disease physicians who prescribe the products. - **Patients covered by public or private reimbursement** (secondary) — Patients whose access depends on NRDL inclusion, supplemental insurance, or hospital coverage. - Third-party distributors that purchase product for resale - Hospitals and major medical centers that ultimately use the drugs - Healthcare providers treating oncology, autoimmune, and infection cases - Patients reached through reimbursement and hospital access channels - Commercial partners in promotional and collaboration arrangements ## Geography The business is centered in Greater China, especially mainland China, where most product revenue is generated and where the commercial organization covers major medical centers. Zai Lab is incorporated in the United States but operates manufacturing and operating subsidiaries in mainland China, with additional holding and financing entities outside mainland China. - **Mainland China / Greater China** (100%) — Product revenue is described as primarily derived from mainland China. - Mainland China is the core commercial market - Greater China coverage is supported by hospital-focused sales teams - Suzhou, China hosts manufacturing facilities for commercial and clinical supply - Hong Kong entities are used for holding and financing - U.S. incorporation provides the parent-company structure ## Strategy Zai Lab’s strategy is to expand patient access to its commercial products while advancing a pipeline across oncology, immunology, neuroscience, and infectious disease. It also emphasizes business development, strategic partnerships, and internal discovery to broaden its portfolio and support future launches and new indications. - **Increase access and adoption of commercial products** (short-term) — Broader reimbursement and hospital coverage drive prescription volume in China’s specialty-drug market. - **Advance pipeline and new indications** (medium-term) — New approvals and label expansions can extend product life cycles and diversify revenue. - **Strengthen business development and partnerships** (medium-term) — Licensing and collaboration agreements provide access to external assets and commercialization rights. - Expand access through NRDL inclusion and supplemental insurance - Increase hospital coverage and penetration for commercial products - Advance internal R&D and late-stage clinical pipeline assets - Use licensing and collaboration agreements to broaden the portfolio - Support commercialization with medical affairs, market access, and distributor management ## Risks Zai Lab faces regulatory, geopolitical, and execution risks tied to operating a China-centered biopharmaceutical business with U.S. listing exposure. Its revenue depends heavily on a limited number of distributors and on reimbursement, hospital adoption, supply continuity, and compliance with complex Chinese and cross-border rules. - **Distributor concentration** [high] — A limited number of distributors account for a meaningful share of product revenue, so loss of a major customer could reduce sales quickly. - **China-U.S. geopolitical and regulatory risk** [high] — The company is U.S.-listed but operates primarily in mainland China, exposing it to policy, capital-flow, and compliance constraints. - **Regulatory and data compliance** [high] — Biopharma operations require compliance with drug, cybersecurity, personal information, and human genetic resource rules. - **Commercial adoption and reimbursement risk** [medium] — Sales depend on hospital access, NRDL inclusion, and supplemental insurance coverage. - **Supply and manufacturing execution** [medium] — The company relies on internal and third-party manufacturing for commercial and clinical supply. - **Cybersecurity and third-party dependence** [medium] — Sensitive clinical, commercial, and personal data move through vendors and cloud systems. - Heavy dependence on distributors concentrates customer and credit risk - China-U.S. relations can affect operations, capital flows, and market access - Regulatory compliance burden spans drug, data, and human genetic rules - Product supply or adoption issues can disrupt revenue growth - Cybersecurity and third-party vendor risks can affect confidential data and operations ## Accounting Revenue is recognized when products are delivered to distributors, but reported net sales are reduced by rebates and returns, making estimate quality important. The company also records collaboration revenue, royalty-related costs, inventory provisions, and share-based compensation, all of which can materially affect period-to-period comparability. - **Revenue recognition and rebate reserves** — Net product revenue and gross-to-net deductions - **Inventory provisions** — Cost of product revenue and margins - **License and collaboration accounting** — Collaboration revenue and royalty expense timing - **Foreign currency remeasurement** — Other income/expense and net earnings - **Share-based compensation** — Operating expenses - Point-in-time revenue recognition on delivery to distributors - Rebate accruals reduce net product revenue and require judgment - Inventory provisions can affect cost of product revenue - License and collaboration milestones can create uneven revenue/cost timing - Foreign currency remeasurement affects reported earnings --- *Last updated: 2026-04-29T05:11:34.796622+00:00*